Does #Sotrovimab remain effective against #Omicron sublineage BA.2? Here is another preprint on the issue, this time published by researchers from @Vir_Biotech , the company that produces Sotrovimab and a second, closely related monoclonal antibody. While there is (1/4) 
a numerical difference between BA.2 and other variants in a pseudovirus model, the company says that overall, neutralisation activity is sustained in BA.2, which would suggest sustained clinical effectiveness.
-
„Sotrovimab was tested against an extended panel of (2/4)
-
„Sotrovimab was tested against an extended panel of (2/4)
pseudotyped viruses incorporating emerging variants as well as variants currently or previously deemed as Variants of Concern (VOC) or Variants of Interest (VOI) by the World Health Organization (WHO). Sotrovimab neutralized all variants tested with (3/4)
fold changes in IC50s of ≤3.3-fold observed for 21 of 22 variants assessed (Table 2), while a 16-fold change in IC50 was observed for the Omicron BA.2 variant (Table 2, Figure 1e).“
(4/4)
(4/4)
Der Link: biorxiv.org/content/10.110…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
